Severe toxicity from checkpoint protein inhibitors: What intensive care physicians need to know?

Virginie Lemiale, Anne-Pascale Meert, François Vincent, Michael Darmon, Philippe P.R. Bauer, Andry Van de Louw and Elie Azoulay

ULB Institutional Repository from ULB -- Universite Libre de Bruxelles

Abstract: Checkpoint protein inhibitor antibodies (CPI), including cytotoxic T-lymphocyte-associated antigen 4 inhibitors (ipilimumab, tremelimumab) and the programmed cell death protein 1 pathway/programmed cell death protein 1 ligand inhibitors (pembrolizumab, nivolumab, durvalumab, atezolizumab), have entered routine practice for the treatment of many cancers. They improve the outcome for many cancers, and more patients will be treated with CPI in the future. Although CPI can lead to adverse events (AE) less frequently than for chemotherapy, their use can require intensive care unit admission in case of severe immune-related adverse events (IrAE). Moreover, some of these events, particularly late events, are poorly documented, so a high level of suspicion should be maintained for patients receiving CPI. Intensivists should be aware in general of the known complications and appropriate management of these AE. Nevertheless, a multidisciplinary collaboration remains essential for their diagnosis and management. This review described the most severe complications related to CPI.

Keywords: Adverse events; Cancer; ICU; Immunotherapy (search for similar items in EconPapers)
Date: 2019-12
Note: SCOPUS: re.j
References: View complete reference list from CitEc
Citations:

Published in: Annals of intensive care (2019) v.9 n° 1

Downloads: (external link)
https://dipot.ulb.ac.be/dspace/bitstream/2013/284907/1/doi_268534.pdf Full text for the whole work, or for a work part (application/pdf)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:ulb:ulbeco:2013/284907

Ordering information: This working paper can be ordered from
http://hdl.handle.ne ... lb.ac.be:2013/284907

Access Statistics for this paper

More papers in ULB Institutional Repository from ULB -- Universite Libre de Bruxelles Contact information at EDIRC.
Bibliographic data for series maintained by Benoit Pauwels ().